Short answer
Keros Therapeutics, Inc. (KROS) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). $5 million common-stock repurchase program approved after receiving a $20 million Takeda development milestone.
Keros Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- $5 million common-stock repurchase program approved after receiving a $20 million Takeda development milestone
- Cash and equivalents totaled $259.5 million as of September 30, 2026
- Post-milestone and repurchase cash expected to fund operations and capital expenditures into 2029
- Buyback signals management confidence while returning a portion of milestone proceeds to shareholders
Item EX-99.1 · Exhibit EX-99.1
- $5 million share repurchase authorization following $20 million elritercept development milestone payment from Takeda
- Capital return signals management views repurchases as an attractive use of milestone proceeds
- Repurchases may occur in open-market transactions, with timing and amounts dependent on market conditions
- Program creates no purchase obligation and may be modified, suspended or discontinued at any time
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Keros Therapeutics, Inc. 8-K filings
Get the next KROS 8-K as it lands
Follow KROS for push alerts, or ask the research agent what this filing means.